Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma.

Liver cancer·2026
Same author

Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

Journal of gastroenterology and hepatology·2026
Same author

Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study.

Hepatology (Baltimore, Md.)·2026
Same author

Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.

Hepatology research : the official journal of the Japan Society of Hepatology·2026
Same author

Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab.

Hepatology research : the official journal of the Japan Society of Hepatology·2026
Same author

On-Demand Loco-Regional Treatment for Intrahepatic Lesions Improves Treatment Outcomes in Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma.

Cancers·2026

Related Experiment Video

Updated: Jun 22, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Systemic abnormalities in liver disease.

Masami Minemura, Kazuto Tajiri, Yukihiro Shimizu

    World Journal of Gastroenterology
    |June 26, 2009
    PubMed
    Summary

    Patients with advanced liver disease frequently develop serious systemic issues, particularly affecting the heart, lungs, and kidneys. Early recognition and management of these cardiopulmonary and renal complications are crucial for improving patient outcomes.

    Area of Science:

    • Internal Medicine
    • Hepatology
    • Cardiology
    • Nephrology

    Background:

    • Systemic abnormalities are common in patients diagnosed with liver disease.
    • Advanced liver disease frequently co-occurs with cardiopulmonary and renal complications.
    • These co-occurring conditions significantly impact patient prognosis and quality of life.

    Discussion:

    • The presence of cardiopulmonary or renal diseases in advanced liver disease patients indicates a serious condition.
    • These systemic issues can be a determining factor in the overall health trajectory and survival rates of patients.
    • Multidisciplinary attention from hepatologists and non-hepatologists is essential for comprehensive patient management.

    Key Insights:

    • Liver disease patients are susceptible to serious systemic complications, including heart, lung, and kidney problems.

    More Related Videos

    Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
    11:06

    Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

    Published on: January 31, 2022

    Human Liver Spheroids from Peripheral Blood for Liver Disease Studies
    09:51

    Human Liver Spheroids from Peripheral Blood for Liver Disease Studies

    Published on: January 27, 2023

    Related Experiment Videos

    Last Updated: Jun 22, 2026

    Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
    09:44

    Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

    Published on: November 27, 2019

    Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
    11:06

    Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

    Published on: January 31, 2022

    Human Liver Spheroids from Peripheral Blood for Liver Disease Studies
    09:51

    Human Liver Spheroids from Peripheral Blood for Liver Disease Studies

    Published on: January 27, 2023

  • Cardiopulmonary and renal issues are particularly concerning in advanced stages of liver disease.
  • Proactive monitoring and management of these systemic abnormalities are vital.

    • Outlook:

    • Future research should focus on integrated care models for liver disease patients with systemic comorbidities.
    • Developing targeted interventions for cardiopulmonary and renal dysfunction in liver disease is a priority.
    • Enhanced collaboration between specialists will improve patient outcomes and quality of life.